Metformin Therapy in Type 1 Diabetes Mellitus.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of exogenous insulin and incorrect nutritional habits are conducive to obesity and excess weight. This leads to the development of insulin resistance, even in patients with type 1 diabetes mellitus. The purpose of this study is to assess the effects of metformin as adjunctive therapy on anthropometric parameters, insulin resistance and metabolic control in overweight and obese patients with type 1 diabetes mellitus.

The study group consists of 200 Caucasian type 1 diabetic patients with elevated adipose tissue content as measured by electrical bioimpedance, treated at the Poznan University of Medical Sciences Department of Diabetology in 2009-2014. All patients have type 1 diabetes diagnosed by autoimmune antibodies, and are treated with intensive insulin therapy. This group is divided into metformin treated arm (group I+ M, 100 subjects), the remaining 100 patients are treated with insulin alone (control group, group I). Metformin is administered at least 6 months at a mean dose of 1000 mg/day.

The investigators would like to assess the impact of metformin treatment on metabolic control, insulin resistance and anthropometric parameters in overweight and obese patients with type 1 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Loss of Control of Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Type 1 diabetes mellitus, metformin, insulin resistance, obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years \<60 years,
* duration of diabetes \>3 years,
* lack of metabolic control- HbA1C\>7,5% (despite participation in 5-day WHO education program)
* treated with intensive insulin therapy

Exclusion Criteria

* metabolically decompensate diabetes with acetonuria,
* suspected lack of compliance,
* lack of glucose and ketones self-monitoring,
* hypoglycaemic unawareness or recurrent severe hypoglycemia (defined as more than two episodes of hypoglycemia lowered than 60 mg/dl with loss of consciousness, required assistance to treat) in the past 3 months,
* recurrent diabetic ketoacidosis (more than two episodes in the past year)
* another serious medical illness,
* pregnancy or sexually active woman unwilling to take birth control.
* renal impairment (estimated on the value calculated glomerular filtration rate using the MDRD formula-estimated glomerular filtration rate, eGFR\<45 mL / min
* liver cell damage Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) greater than twice the upper normal limit),
* history of drug or alcohol abuse or those who used this drug before
* changes in the way of antihypertensive and antihyperlipemic treatment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Agnieszka Zawada

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dariusz Naskręt, PhD

Role: PRINCIPAL_INVESTIGATOR

Poznań University of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Internal Medicine and Diabetology, Raszeja Hospital

Poznan, Great Poland, Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Agnieszka Zawada, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MTiT1DM

Identifier Type: -

Identifier Source: org_study_id